Beta-catenin expression is prognostic of improved non-small cell lung cancer survival
journal contribution
posted on 2023-05-17, 16:18 authored by Chiu, CG, Chan, SK, Fang, ZA, Masoudi, H, Wood-Baker, R, Jones, SJM, Gilks, B, Laskin, J, Wiseman, SMINTRODUCTION: The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients. METHODS: Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry. RESULTS: Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage. CONCLUSIONS: Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC. © 2012 Elsevier Inc.
History
Publication title
American Journal of SurgeryVolume
203Issue
5Pagination
654-659ISSN
0002-9610Department/School
Tasmanian School of MedicinePublisher
Elsevier Inc.Place of publication
1600 John F Kennedy Blvd, Philadelphia, USARights statement
Copyright 2012 Elsevier Inc.Repository Status
- Restricted
Socio-economic Objectives
Clinical health not elsewhere classifiedUsage metrics
Categories
Keywords
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC